[ad_1]
The use of the AstraZeneca vaccine will also be suspended in Ireland until new information on possible side effects is received, local health authorities reported Sunday.
Following the example of Norway, Bulgaria, Denmark and Iceland decided to suspend on Thursday, and a similar decision was made on Sunday in the Italian province of Piedmont.
This is because some patients have experienced severe blood clots after using the vaccine, although a clear causal relationship has not been scientifically proven. According to a report on Saturday, there have already been four such cases in Norway.
The suspension in Ireland was warned by the competent health authority as a precautionary measure based on the latest news, writes MTI.
Stopping vaccines is expected to further slow immunization in Europe, the German news agency DPA noted.
The AstraZeneca vaccine was previously discontinued in Austria after a nurse died of similar symptoms, but then the British-Swedish vaccine was given the green light again. Yesterday we wrote that a Slovak teacher had also died two weeks after being given the vaccine.
In Italy, a teacher also died one day after vaccination after receiving the AstraZeneca vaccine in Biella. The circumstances of his death are still under investigation, but use of the British-Swedish vaccine has been discontinued with immediate effect. Those who signed up for this vaccine on Sunday were sent home from vaccination stations. At the moment, only the Pfizer-BioNTech and Moderna vaccines remain in the region. Piedmont Provincial Health Councilor Luigi Genesio Icardi called the suspension a precautionary decision.
Previously, the use of two batches of AstraZeneca was discontinued in Sicily after blood clots were also detected in some cases after vaccination. An investigation has been launched into the death of a soldier.
Following the publication of our article, the pharmaceutical company wrote in a statement Sunday that it believes that no scientific data suggests that the company’s developed coronavirus vaccine would increase the risk of blood clots.
The company emphasized that a safety study of more than 17 million doses of vaccines administered so far in the European Union and the United Kingdom had not provided any evidence of an increased risk of developing pulmonary embolism, deep vein thrombosis or abnormal platelet counts.
[ad_2]
